
DD Stock Forecast & Price Target
DD Analyst Ratings
Bulls say
DuPont de Nemours's positive outlook is supported by strong organic sales growth in its Healthcare & Water segments, driven by robust demand for medical packaging, biopharma, reverse osmosis, and ion exchange products. The company's strategic shift towards new products, with a vitality index improvement target from 35% to 45%, is expected to enhance pricing and sales mix, further bolstering revenue streams. Additionally, the Electronics & Industrial segment is poised for volume growth fueled by advancements in 5G technology, the Internet of Things, and increased technological investments, thereby positioning DuPont favorably in a competitive market landscape.
Bears say
DuPont de Nemours faces significant challenges due to anticipated delays in synergy realization stemming from the 2019 merger, which could hinder the company's ability to enhance profitability. Furthermore, ongoing weakness in the electronics and construction markets is likely to negatively impact revenue generation from critical segments of its diversified portfolio. Additionally, a slower-than-expected recovery in China further complicates the outlook, potentially leading to persistent underperformance in key business areas that are crucial for DuPont's financial health.
This aggregate rating is based on analysts' research of DuPont de Nemours and is not a guaranteed prediction by Public.com or investment advice.
DD Analyst Forecast & Price Prediction
Start investing in DD
Order type
Buy in
Order amount
Est. shares
0 shares